Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Marinus Pharma CS
(NQ:
MRNS
)
1.395
-0.025 (-1.76%)
Streaming Delayed Price
Updated: 1:30 PM EDT, Sep 5, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Marinus Pharma CS
< Previous
1
2
3
4
5
6
7
Next >
MRNS Class Action Alert: Robbins LLP Reminds Stockholders of the Lead Plaintiff Deadline in the Class Action Against Marinus Pharmaceuticals, Inc.
June 11, 2024
From
Robbins LLP
Via
GlobeNewswire
MARINUS ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Marinus Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm
June 10, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Marinus Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - MRNS
June 10, 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
Marinus Pharmaceuticals Inc. (NASDAQ: MRNS) is a Stock Spotlight on 1/5
January 05, 2024
Via
Investor Brand Network
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Marinus Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - MRNS
June 10, 2024
WHY: NEW YORK, NY - (NewMediaWire) - June 10, 2024 - Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of...
Via
TheNewswire.com
Topics
Lawsuit
Exposures
Financial
Legal
MARINUS PHARMACEUTICALS, INC. (NASDAQ: MRNS) INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Marinus Pharmaceuticals, Inc.
June 10, 2024
From
Bernstein Liebhard LLP
Via
GlobeNewswire
ROSEN, NATIONAL TRIAL COUNSEL, Encourages Marinus Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - MRNS
June 08, 2024
WHY: NEW YORK, NY - (NewMediaWire) - June 08, 2024 - Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of...
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
ROSEN, NATIONAL TRIAL COUNSEL, Encourages Marinus Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - MRNS
June 08, 2024
WHY: NEW YORK, NY - (NewMediaWire) - June 08, 2024 - Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of...
Via
TheNewswire.com
Topics
Lawsuit
Exposures
Financial
Legal
Marinus Pharmaceuticals Investor Notice: Robbins LLP Reminds Stockholders to Seek Representation in the MRNS Class Action
June 07, 2024
From
Robbins LLP
Via
Business Wire
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Marinus Pharmaceuticals, Inc. with Losses to Contact the Firm
June 07, 2024
From
The Schall Law Firm
Via
Business Wire
MARINUS ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Marinus Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm
June 06, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Marinus Pharmaceuticals, Inc. with Losses to Contact the Firm
June 06, 2024
From
Schall Law
Via
GlobeNewswire
MRNS INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Marinus Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
June 06, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
MARINUS PHARMACEUTICALS, INC. (NASDAQ: MRNS) INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Marinus Pharmaceuticals, Inc.
June 06, 2024
From
Bernstein Liebhard LLP
Via
GlobeNewswire
Stockholder Alert: Robbins LLP Informs Investors that a Shareholder Has Filed a Class Action Against Marinus Pharmaceuticals, Inc. (MRNS)
June 05, 2024
From
Robbins LLP
Via
GlobeNewswire
MRNS INVESTOR NEWS: ROSEN, A LEADING LAW FIRM, Encourages Marinus Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – MRNS
June 05, 2024
From
The Rosen Law Firm PA
Via
GlobeNewswire
EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit on Behalf of Marinus Pharmaceuticals, Inc. Investors – MRNS
June 05, 2024
From
The Rosen Law Firm, P.A.
Via
Business Wire
Marinus Pharmaceuticals Announces Key Business Updates for Tuberous Sclerosis Complex Program
May 17, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results
May 08, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals to Present at the RBC Capital Markets 2024 Global Healthcare Conference
May 02, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals to Provide Business Update and Report First Quarter 2024 Financial Results on May 8, 2024
May 01, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Marinus Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
April 15, 2024
From
Schall Law
Via
GlobeNewswire
Marinus Pharmaceuticals Provides Update on the Phase 3 RAISE Trial and Reports Preliminary First Quarter 2024 Financial Results
April 15, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
April 05, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Comments on Patent Challenge by Ovid Therapeutics Inc. and Provides Update on Marinus’ Post Grant Review
March 27, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
March 05, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals to Present at Upcoming Investor Conferences
February 21, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024
February 20, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
February 16, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
January 04, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.